Article thumbnail
Location of Repository

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

By Ursula Amstutz, Simone Farese, Stefan Aebi and Carlo R Largiadèr
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2584619
Provided by: PubMed Central

Suggested articles

Citations

  1. (2004). A: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
  2. (1996). AH: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency.
  3. (2003). Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer
  4. (2004). Diasio R: Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer
  5. (2002). Diasio R: Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics
  6. (2005). Diasio R: Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res
  7. (2008). Diasio RB: Predicting fluorouracil toxicity: can we finally do it?
  8. (2007). Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FUrelated toxicity.
  9. (2006). E: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther
  10. (2008). et al.: Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group. J Clin Oncol
  11. (1998). et al.: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.
  12. (1996). Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
  13. (2005). Gross E: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res
  14. (2000). HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics
  15. (2001). Höffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res
  16. Largiadèr CR: Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment.
  17. (2004). Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res
  18. (2000). McLeod HL: Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
  19. (2000). Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta
  20. (2006). Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res
  21. (1994). Population study of dihydropyrimidine dehydrogenase in cancer patients.
  22. (2004). Schömig E: Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie
  23. Terminology Criteria for Adverse Events
  24. (2004). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.